IgA nephropathy: What patients are at risk of progression to end-stage renal disease and how should they be treated?

[1]  M. Goicoechea,et al.  Changes in the clinical presentation of immunoglobulin A nephropathy: data from the Spanish Registry of Glomerulonephritis , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  G. Ariceta,et al.  Mesangial C4d Deposits in Early IgA Nephropathy. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[3]  Hong Zhang,et al.  Mannose-Binding Lectin Levels Could Predict Prognosis in IgA Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[4]  S. Rodríguez de Córdoba,et al.  Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy. , 2017, Kidney international.

[5]  T. Cavero,et al.  Remission of Hematuria Improves Renal Survival in IgA Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[6]  R. Coppo,et al.  Persistent Microscopic Hematuria as a Risk Factor for Progression of IgA Nephropathy: New Floodlight on a Nearly Forgotten Biomarker. , 2017, Journal of the American Society of Nephrology : JASN.

[7]  M. Falchi,et al.  Circulating complement factor H–related proteins 1 and 5 correlate with disease activity in IgA nephropathy , 2017, Kidney international.

[8]  David W. Johnson,et al.  Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial , 2017, JAMA.

[9]  C. Zeng,et al.  Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  F. Locatelli,et al.  Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial , 2017, The Lancet.

[11]  Mark Haas,et al.  Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. , 2017, Kidney international.

[12]  B. Rovin,et al.  A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. , 2017, Journal of the American Society of Nephrology : JASN.

[13]  M. Haas,et al.  IgA Nephropathy. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[14]  J. Levy,et al.  Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment. , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  J. Egido,et al.  Haematuria as a risk factor for chronic kidney disease progression in glomerular diseases: A review , 2016, Pediatric Nephrology.

[16]  Vladimir Tesar,et al.  Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study. , 2015, Journal of the American Society of Nephrology : JASN.

[17]  R. Coppo,et al.  The MEST score provides earlier risk prediction in IgA nephropathy. , 2015, Kidney international.

[18]  C. Fitzner,et al.  Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. , 2015, The New England journal of medicine.

[19]  Marina Sánchez,et al.  Association of C4d deposition with clinical outcomes in IgA nephropathy. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[20]  L. Morando,et al.  Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments , 2014, Kidney international.

[21]  J. Floege,et al.  Treatment of IgA nephropathy and Henoch–Schönlein nephritis , 2013, Nature Reviews Nephrology.

[22]  M. Goicoechea,et al.  Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. , 2012, Journal of the American Society of Nephrology : JASN.

[23]  Loreto Gesualdo,et al.  Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis , 2012, PLoS genetics.

[24]  A. Ortiz,et al.  AKI associated with macroscopic glomerular hematuria: clinical and pathophysiologic consequences. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[25]  B. Kasiske,et al.  KDIGO Clinical Practice Guideline for Glomerulonephritis , 2012 .

[26]  S. Tang,et al.  Long-term study of mycophenolate mofetil treatment in IgA nephropathy. , 2010, Kidney international.

[27]  F. Schena,et al.  Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  J. Scholey,et al.  Remission of proteinuria improves prognosis in IgA nephropathy. , 2007, Journal of the American Society of Nephrology : JASN.

[29]  L. Peruzzi,et al.  IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. , 2007, Journal of the American Society of Nephrology : JASN.

[30]  G. Usera,et al.  Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[31]  S. Tang,et al.  Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. , 2005, Kidney international.

[32]  E. Morales,et al.  Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. , 2003, Journal of the American Society of Nephrology : JASN.

[33]  E. Bergstralh,et al.  Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  F. Locatelli,et al.  Corticosteroids in IgA nephropathy: a randomised controlled trial , 1999, The Lancet.

[35]  L. Ruilope,et al.  Acute worsening of renal function during episodes of macroscopic hematuria in IgA nephropathy. , 1985, Kidney international.

[36]  F. Ferrario,et al.  IgA-mesangial nephropathy (Berger's disease) with rapid decline in renal function. , 1981, Clinical nephrology.